Mamnun, Anis Zuhaida (2020) Anti-Proliferation Properties of Astaxanthin on Human Umbilical Vein Endothelial Cell (HUVEC) Stimulated by VEGF. [Project Paper] (Submitted)
|
Text
FPSK2 2020 39.pdf Download (1MB) |
Abstract
Angiogenesis is playing a critical role in cancer growth and metastasize. Tumor cells induced new blood vessels formation in order to get nutrients and oxygen to grow. Thus, anti-angiogenic agent is a good candidate in anti-cancer treatment. Current anti-angiogenic agent such as AstraZeneca and Wyeth, exhibit unwanted side effects. Thus, it is a need to search for a new therapeutic agent to against angiogenesis with less or without side effect. Objective: The aim of this study is to determine the anti-proliferative properties of Astaxanthin (ATX) in human umbilical vein endothelial cells (HUVECs) induced by vascular endothelial growth factor (VEGF). Methodology: Cytotoxicity effect of different concentration of ATX on endothelial cell and anti-proliferative effect of ATX on VEGF-induced HUVECs proliferation was determined by using MTT. Result: Cytotoxicity assay revealed cell treated with ATX getting less viable when the concentration increased. ATX at concentration of 50 M killed 31% of the HUVECs when treated for 24 hours. In addition, LC50 concentration was 82.08 μM which revealed by the MTT assay. On the other hand, HUVECs treated with VEGF significantly (p<0.05) increased cell proliferation, but this suppressed by ATX treatment with concentration range from 3.125 – 50 M. The maximum inhibition rate was produced by 50 M was 96.99 μM. This could be due to cytotoxicity effect of the ATX. Conclusion: In conclusion, ATX exhibited anti-proliferative activity against VEGF-stimulated HUVECs.
| Item Type: | Project Paper |
|---|---|
| Faculty: | Faculty of Medicine and Health Science |
| Depositing User: | Ms. Nor Safa'aton Saidin |
| Date Deposited: | 23 Aug 2023 00:33 |
| Last Modified: | 23 Aug 2023 00:33 |
| URI: | http://psaspb.upm.edu.my/id/eprint/1329 |
Actions (login required)
![]() |
View Item |
